c-met/hgfr — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T7900	BAY-474		c-Met/HGFR
	BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe		c-Met/HGFR
T2293	SGX-523		Raf , p38 MAPK , c-Met/HGFR , Bcr-Abl
	SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.		Raf , p38 MAPK , c-Met/HGFR , Bcr-Abl
T5349	SCR-1481B1	c-Met inhibitor 2	VEGFR , c-Met/HGFR
	SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor		VEGFR , c-Met/HGFR
T6094	MK-2461	MK2461	c-Met/HGFR
	MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an average inhibitory concentration (IC50) of 2.5 nM.		c-Met/HGFR
T6095	JNJ-38877605		c-Met/HGFR
	JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.		c-Met/HGFR
T10655	c-Met inhibitor 1		c-Met/HGFR
	c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.		c-Met/HGFR
T6378	AMG-458	AMG 458	c-Met/HGFR
	AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.		c-Met/HGFR
T37596	Terevalefim		c-Met/HGFR
	Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.		c-Met/HGFR
T6154	SU11274	Met Kinase Inhibitor,PKI-SU11274	Apoptosis , VEGFR , FGFR , c-Met/HGFR , CDK , Autophagy
	SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.		Apoptosis , VEGFR , FGFR , c-Met/HGFR , CDK , Autophagy
T6260	AMG-208	AMG 208	P450 , c-Met/HGFR
	AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.		P450 , c-Met/HGFR
T3274	S49076		FGFR , c-Met/HGFR , TAM Receptor
	S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.		FGFR , c-Met/HGFR , TAM Receptor
T6117	Tivantinib	ARQ 197	Apoptosis , c-Met/HGFR
	Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.		Apoptosis , c-Met/HGFR
T2680	NVP-BVU972		c-Met/HGFR
	NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.		c-Met/HGFR
TQ0041	Ningetinib Tosylate		VEGFR , c-Met/HGFR , TAM Receptor
	Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.		VEGFR , c-Met/HGFR , TAM Receptor
T6128	PHA-665752	PHA 665752,PHA665752	Apoptosis , VEGFR , FGFR , c-Met/HGFR , Bcr-Abl , Autophagy
	PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.		Apoptosis , VEGFR , FGFR , c-Met/HGFR , Bcr-Abl , Autophagy
T11162	EGFR-IN-8		EGFR , c-Met/HGFR
	EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC.		EGFR , c-Met/HGFR
T2419	BMS-794833		VEGFR , c-Met/HGFR
	BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.		VEGFR , c-Met/HGFR
T15617	JNJ-38877618	OMO-1	c-Met/HGFR
	JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).		c-Met/HGFR
T8409	SYN1143	RON-IN-1,AMG-1	c-Met/HGFR
	SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively.		c-Met/HGFR
T5478	SRI 31215 TFA	SRI 31215	c-Met/HGFR
	SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM,		c-Met/HGFR